



UNITED STATES PATENT AND TRADEMARK OFFICE

141
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,826	07/21/2005	Viktor McNart	LB/G-32991A/LEK	4902
1095	7590	07/24/2007	EXAMINER	
NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080			MACFARLANE, STACEY NEE	
		ART UNIT		PAPER NUMBER
		1649		
		MAIL DATE		DELIVERY MODE
		07/24/2007		PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/522,826	MENART ET AL.
	Examiner	Art Unit
	Stacey MacFarlane	1649

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 21 July 2005.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-10, 12-17, 19-27 and 29-31 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-10, 12-17, 19-27 and 29-31 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____.
- 5) Notice of Informal Patent Application
- 6) Other: _____.

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1, 3-10, 12-17, and 19-26, drawn to a process for the production of a protein comprising the expression of said protein as a heterologous protein, wherein at least one of the parameters or conditions, which enable the regulation of the composition of inclusion bodies, is adjusted in such a way that the amount (proportion) of the correctly folded precursor of the heterologous protein after expression is increased in said inclusion bodies.

Group 2, claim 2, drawn to a process for the production of a protein comprising performing the biosynthesis of said protein as a heterologous protein in a micro-organism.

Group 3, claim(s) 27 and 29-31, drawn to a process for the production of a protein using a micro-organism, wherein said protein is expressed as a heterologous protein and is formed in inclusion bodies in said micro-organism.

The inventions listed as Groups 1-3 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the single general inventive concept that permeates the groups is the heterologous expression of proteins via the adjustment of one or more parameters regulating the composition of inclusion bodies. The expression "special technical feature" is defined in Rule 13.2 as meaning

those technical features that define a contribution which each of the inventions makes over the prior art. Whether a particular feature makes a contribution over the prior art, is considered with respect to novelty and inventive step. In the instant application, heterologous expression of proteins in microorganism inclusion bodies does not make a contribution over the prior art. The following reference teaches that many heterologous polypeptides accumulate in inclusion bodies upon expression in the micro-organism, *Escherichia coli* and that there are several strategies for altering accumulation such as co-expression of folding proteins or the use of fusion proteins (abstract; Georgiou and Valax, *Current Opinion in Biotechnology* 7: 190-197, published 1996). The prior art recites the common technical feature of Groups 1-3, thus, there is no special technical feature over the prior art and the application lacks Unity of Invention under PCT Rule 13.1.

2. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

(Claims 3 and 4) Elect one of the following heterologous proteins: G-CSF, GM-CSF, M-CSF, EGF, HAS, DNase, FGF, TNF-alpha, TNF-beta, interferons or interleukins.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply

must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: Claim 1 is the generic of Group 1, Claim 2 is generic to Group 2, and Claim 27 is generic to Group 3.

3. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: The process of expressing heterologous proteins in the inclusion bodies of micro-organisms is materially distinct depending upon the heterologous protein that is to be expressed. There is no association disclosed for the species listed above so as to link them as a having a corresponding special technical feature. The species include growth factors and cytokines that have each achieved a separate status in the art and therefore are not corresponding.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification,

recognized divergent subject matter and non-coextensive literature searches, which also includes searching different electronic databases, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacey MacFarlane whose telephone number is (571) 270-3057. The examiner can normally be reached on Monday-Thursday 6:30AM-4:00 PM & ALT. Fridays, EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Stacey MacFarlane
Examiner
Art Unit 1649

SNM


OLGA N. CHERYSHEV, PH.D.
PRIMARY EXAMINER